Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.72 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.72 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.49 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 7/20 | 0.48 |
| ▸ | GRM5 | P41594 | 3/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | FABP6 | P51161 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18333426 | 0.85 | CDC7 (0.76) | CDC7DBF4PARP10PARP1PARP11 | |
| SCHEMBL386986 | 0.77 | PARP10 (0.49) | CDC7DBF4PARP10PARP1PARP11 | |
| SCHEMBL21963442 | 0.75 | CDC7 (0.57) | CDC7DBF4PARP10PARP1PARP11 | |
| SCHEMBL24847020 | 0.74 | CDC7 (0.63) | CDC7DBF4PARP10PARP1PARP11 | |
| SCHEMBL24847019 | 0.72 | CDC7 (0.59) | CDC7DBF4PARP10PARP11MAPKAPK2 | |
| SCHEMBL8167145 | 0.71 | PARP10 (0.76) | PARP10PARP1PARP11GRM5PDPK1 | |
| SCHEMBL3003038 | 0.71 | HTR2C (0.44) | CDC7DBF4PARP1PDPK1 | |
| SCHEMBL797294 | 0.71 | PARP10 (0.76) | PARP10PARP1PARP11GRM5MAPKAPK2 | |
| SCHEMBL798998 | 0.71 | RIPK3 (0.44) | CDC7DBF4PARP10PARP1PARP11 | |
| SCHEMBL798024 | 0.69 | CDC7 (0.54) | CDC7DBF4PARP10PARP1PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880684-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880200-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102243-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102245-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CDC7 1205/4885DBF4 3433/4885PARP10 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.